Kraig Biocraft Laboratories Increases Monster Silk(TM) Silkworm Yields at the Company's New Laboratory
June 27 2012 - 6:05AM
Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB.PK) (the "Company" or
"Kraig") announces that the Company's recently opened private
laboratory has significantly increased Kraig's ability to generate
its proprietary Monster Silk™ production platform silkworms.
The initial focus of the Company's facility is to assist in the
commercialization of Kraig's product, Monster Silk™, by
significantly ramping up production of the Company's proprietary
transgenic silkworms that produce Monster Silk™, a new recombinant
spider silk based fiber with potentially broad applications for
consumers and industry in the multi-billion dollar marketplace for
textiles and performance polymers.
"Our main goal, for the Company's recently opened laboratory,
was to rapidly increase our ability to raise our Monster Silk™
silkworms. In the short time it's been operational, we have
effectively quadrupled our ability to produce the transgenic
silkworms, which produce Monster Silk™," said Company founder and
CEO, Kim Thompson.
"We knew that the increase in our laboratory production would be
fundamental to the commercialization of Monster Silk™," continued
Thompson. "Now that the new laboratory is working as planed,
we are looking to exponentially expand our production of Monster
Silk™."
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com) is a fully
reporting biotechnology company that has achieved a series of
scientific breakthroughs in its work with spider silk gene
sequences, with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking
Information
Statements in this press release about the Company's future and
expectations other than historical facts are "forward-looking
statements." These statements are made on the basis of management's
current views and assumptions. As a result, there can be no
assurance that management's expectations will necessarily come to
pass. These forward-looking statements generally can be identified
by phrases such as "believes," "plans," "expects," "anticipates,"
"foresees," "estimated," "hopes," "develops," "researching,"
"research," "potential," "could" or other words or phrases of
similar import. Similarly, statements in this release that describe
the Company's business strategy, outlook, objectives, plans,
intentions or goals should all be considered forward-looking
statements. All such forward-looking statements are subject to
certain risks and uncertainties that could cause actual results to
differ materially from those in forward-looking statements.
Management cautions that its ability to further its research, and
create commercially-viable products may be affected by the
competitive environment, the Company's financial condition and its
ability to raise sufficient capital to meet the financial
obligations of its business plan and to fund its continuing
operations.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any security and shall not
constitute an offer, solicitation or sale of any securities in any
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of such jurisdiction.
CONTACT: Ben Hansel
Hansel Capital
benh@ttfsco.com
(720) 288-8495
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From May 2024 to Jun 2024
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From Jun 2023 to Jun 2024